Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Aprea Therapeutics appoints Fouad Namouni, Richard Peters to board » 07:14
06/29/20
06/29
07:14
06/29/20
07:14
APRE

Aprea Therapeutics

$38.33 /

-1.07 (-2.72%)

, BMY

Bristol-Myers

$57.52 /

-0.63 (-1.08%)

Aprea Therapeutics (APRE)…

Aprea Therapeutics (APRE) announced the appointments of Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to its Board of Directors. In addition, Guido Magni, M.D., Ph.D. will step down from the Company's Board of Directors, effective June 30, 2020. Fouad Namouni most recently serving as Senior Vice President & Head of Oncology Development at Bristol-Myers Squibb (BMY). Richard Peters currently serves as President, Chief Executive Officer and Director at Yumanity Therapeutics.

ShowHide Related Items >><<
BMY Bristol-Myers
$57.52 /

-0.63 (-1.08%)

APRE Aprea Therapeutics
$38.33 /

-1.07 (-2.72%)

APRE Aprea Therapeutics
$38.33 /

-1.07 (-2.72%)

06/22/20
Fly Intel: Top five analyst initiations
06/22/20 H.C. Wainwright
Aprea Therapeutics initiated with a Neutral at H.C. Wainwright
04/21/20
Fly Intel: Top five analyst initiations
04/20/20
Baird starts Aprea Therapeutics with Outperform on APR-246 potential
BMY Bristol-Myers
$57.52 /

-0.63 (-1.08%)

06/22/20 Morgan Stanley
Morgan Stanley sees Eliquis patent being upheld, ruling being 'imminent'
06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
BMY Bristol-Myers
$57.52 /

-0.63 (-1.08%)

APRE Aprea Therapeutics
$38.33 /

-1.07 (-2.72%)

  • 03
    Oct
BMY Bristol-Myers
$57.52 /

-0.63 (-1.08%)

BMY Bristol-Myers
$57.52 /

-0.63 (-1.08%)

BMY Bristol-Myers
$57.52 /

-0.63 (-1.08%)

Over a week ago
Initiation
Fly Intel: Top five analyst initiations » 09:57
06/22/20
06/22
09:57
06/22/20
09:57
NKLA

Nikola

$65.13 /

-0.77 (-1.17%)

, DKNG

DraftKings

$42.00 /

+0.03 (+0.07%)

, APRE

Aprea Therapeutics

$37.19 /

+ (+0.00%)

, CHX

ChampionX

$9.82 /

+0.055 (+0.56%)

, LLNW

Limelight Networks

$5.15 /

+ (+0.00%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Nikola (NKLA) initiated with a Neutral at JPMorgan. 2. DraftKings (DKNG) initiated with a Buy at Jefferies. 3. Aprea Therapeutics (APRE) initiated with a Neutral at H.C. Wainwright. 4. ChampionX (CHX) initiated with a Buy at BofA. 5. Limelight Networks (LLNW) initiated with a Buy at Lake Street. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
NKLA Nikola
$65.13 /

-0.77 (-1.17%)

LLNW Limelight Networks
$5.15 /

+ (+0.00%)

DKNG DraftKings
$42.00 /

+0.03 (+0.07%)

CHX ChampionX
$9.82 /

+0.055 (+0.56%)

APRE Aprea Therapeutics
$37.19 /

+ (+0.00%)

NKLA Nikola
$65.13 /

-0.77 (-1.17%)

06/22/20 JPMorgan
CNH Industrial price target raised to $8 from $6.50 at JPMorgan
06/22/20 JPMorgan
JPMorgan starts 'fully valued' Nikola with Neutral, $45 price target
06/22/20 JPMorgan
Nikola initiated with a Neutral at JPMorgan
06/17/20
Fly Intel: Top five analyst initiations
DKNG DraftKings
$42.00 /

+0.03 (+0.07%)

06/22/20 Jefferies
DraftKings initiated with a Buy at Jefferies
06/19/20 Susquehanna
DraftKings state launches will cost money, says Susquehanna
06/17/20 Susquehanna
DraftKings equity offering both smart and required, says Susquehanna
06/12/20 Craig-Hallum
New Jersey iGaming revenue accelerates in May, Craig-Hallum says
APRE Aprea Therapeutics
$37.19 /

+ (+0.00%)

06/22/20 H.C. Wainwright
Aprea Therapeutics initiated with a Neutral at H.C. Wainwright
04/21/20
Fly Intel: Top five analyst initiations
04/20/20
Baird starts Aprea Therapeutics with Outperform on APR-246 potential
04/20/20 Baird
Aprea Therapeutics initiated with an Outperform at Baird
CHX ChampionX
$9.82 /

+0.055 (+0.56%)

06/22/20 BofA
ChampionX initiated with a Buy at BofA
06/04/20 Citi
Apergy price target raised to $15 from $12 at Citi
LLNW Limelight Networks
$5.15 /

+ (+0.00%)

06/22/20 Lake Street
Limelight Networks initiated with a Buy at Lake Street
06/08/20 Raymond James
Limelight Networks shares compelling at current levels, says Raymond James
06/08/20 Raymond James
Limelight Networks upgraded to Outperform from Market Perform at Raymond James
04/21/20 Cowen
Limelight Networks upside results and guidance seen, says Cowen
LLNW Limelight Networks
$5.15 /

+ (+0.00%)

DKNG DraftKings
$42.00 /

+0.03 (+0.07%)

APRE Aprea Therapeutics
$37.19 /

+ (+0.00%)

NKLA Nikola
$65.13 /

-0.77 (-1.17%)

DKNG DraftKings
$42.00 /

+0.03 (+0.07%)

NKLA Nikola
$65.13 /

-0.77 (-1.17%)

LLNW Limelight Networks
$5.15 /

+ (+0.00%)

DKNG DraftKings
$42.00 /

+0.03 (+0.07%)

NKLA Nikola
$65.13 /

-0.77 (-1.17%)

LLNW Limelight Networks
$5.15 /

+ (+0.00%)

DKNG DraftKings
$42.00 /

+0.03 (+0.07%)

Initiation
Aprea Therapeutics initiated with a Neutral at H.C. Wainwright » 06:08
06/22/20
06/22
06:08
06/22/20
06:08
APRE

Aprea Therapeutics

$37.19 /

+1.14 (+3.16%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Andrew Fein initiated coverage of Aprea Therapeutics with a Neutral rating and $30 price target. The analyst sees downside risk into the Phase 3 study of myelodysplastic syndrome, expected in Q3. The trial should likely hit its primary endpoint complete response rate, but existing evidence does not suggest elevated probability of success of increased duration of response, a key measurement required for regulatory approval, Fein tells investors in a research note.

ShowHide Related Items >><<
APRE Aprea Therapeutics
$37.19 /

+1.14 (+3.16%)

APRE Aprea Therapeutics
$37.19 /

+1.14 (+3.16%)

04/21/20
Fly Intel: Top five analyst initiations
04/20/20
Baird starts Aprea Therapeutics with Outperform on APR-246 potential
04/20/20 Baird
Aprea Therapeutics initiated with an Outperform at Baird
10/28/19 RBC Capital
Aprea Therapeutics initiated with an Outperform at RBC Capital
APRE Aprea Therapeutics
$37.19 /

+1.14 (+3.16%)

Hot Stocks
Aprea Therapeutics presents results from Phase Ib/II clinical trial of APR-246 » 06:26
06/12/20
06/12
06:26
06/12/20
06:26
APRE

Aprea Therapeutics

$30.16 /

-0.39 (-1.28%)

Aprea Therapeutics…

Aprea Therapeutics announced the oral presentation of updated data from its French Phase 1b/2 clinical trial at the 25th European Hematology Association Annual Meeting. The trial is evaluating the safety and efficacy of APR-246 in combination with azacitidine for the treatment of TP53 mutant myelodysplastic syndromes and acute myeloid leukemia. The clinical trial is sponsored by the Groupe Francophone des Myelodysplasies. As of the April 1 data cutoff, the overall response rate in 28 evaluable MDS patients was 75%, with a 57% complete remission rate, by International Working Group criteria. With a median duration of follow-up of 9.7 months, the median overall survival for all enrolled patients was 12.1 months and in MDS patients was 12.1 months. For patients who remained on treatment for 3 or more cycles of treatment the median OS was higher at 13.7 months versus 2.8 months for patients who were on treatment for fewer than 3 cycles. Relative to baseline, mutant TP53 variant allele frequency was decreased in responding patients by 3 cycles of treatment, including 20 patients who achieved mutant TP53 negativity by next-generation sequencing. "The data from this ongoing trial of eprenetapopt with azacitidine continue to be very encouraging in these most difficult-to-treat TP53 mutant MDS and AML patients, who not only have at least one TP53 mutation but the majority of whom also have high risk cytogenetic abnormalities," said Thomas Cluzeau, M.D., co-lead investigator for the GFM trial. "We continue to observe ORR and CR rates in these patients that are substantially higher than the GFM's experience with azacitidine monotherapy. Furthermore, with increased duration of follow-up, we now also see the emergence of highly encouraging overall survival that appears to be better than azacitidine alone or in combination with others agents in this very high-risk molecular group of patients with a TP53 mutation."

ShowHide Related Items >><<
APRE Aprea Therapeutics
$30.16 /

-0.39 (-1.28%)

APRE Aprea Therapeutics
$30.16 /

-0.39 (-1.28%)

04/21/20
Fly Intel: Top five analyst initiations
04/20/20
Baird starts Aprea Therapeutics with Outperform on APR-246 potential
04/20/20 Baird
Aprea Therapeutics initiated with an Outperform at Baird
10/28/19 RBC Capital
Aprea Therapeutics initiated with an Outperform at RBC Capital
APRE Aprea Therapeutics
$30.16 /

-0.39 (-1.28%)

Over a month ago
Hot Stocks
Aprea Therapeutics completes enrollment of Phase 3 trial in TP53 mutant MDS » 08:13
06/03/20
06/03
08:13
06/03/20
08:13
APRE

Aprea Therapeutics

$25.85 /

-1.7 (-6.17%)

Aprea Therapeutics…

Aprea Therapeutics announced that patient enrollment in its Phase 3 clinical trial evaluating eprenetapopt with azacitidine for the treatment of front-line TP53 mutant myelodysplastic syndromes has been completed. Topline results are expected by year-end 2020. Aprea plans to include the results of the trial in a New Drug Application to the U.S. FDA and a Marketing Authorization Application to the EMA in 2021. The randomized, controlled pivotal Phase 3 trial is designed to evaluate eprenetapopt with azacitidine compared with azacitidine alone as front-line therapy in intermediate, high, and very high risk TP53 mutant MDS patients. The multi-center trial enrolled 154 patients, randomized 1:1 to the two arms with a primary endpoint of CR rate. The trial has 90% power with P-value less than 0.05 to detect a difference in CR rates of 50% in the eprenetapopt-containing arm versus 25% in the azacitidine-only control arm.

ShowHide Related Items >><<
APRE Aprea Therapeutics
$25.85 /

-1.7 (-6.17%)

APRE Aprea Therapeutics
$25.85 /

-1.7 (-6.17%)

04/21/20
Fly Intel: Top five analyst initiations
04/20/20
Baird starts Aprea Therapeutics with Outperform on APR-246 potential
04/20/20 Baird
Aprea Therapeutics initiated with an Outperform at Baird
10/28/19 RBC Capital
Aprea Therapeutics initiated with an Outperform at RBC Capital
APRE Aprea Therapeutics
$25.85 /

-1.7 (-6.17%)

Hot Stocks
Aprea Therapeutics targets submission of IND for APR-548 in 1H20 » 07:36
05/15/20
05/15
07:36
05/15/20
07:36
APRE

Aprea Therapeutics

$34.00 /

+0.32 (+0.95%)

The Company's second…

The Company's second product candidate, APR-548, is a next-generation p53 reactivator with the potential for oral administration. APR-548 is a unique analog of APR-246 and therefore a pro-drug of MQ. APR-548 exhibits high oral bioavailability in preclinical testing and is being developed in an oral dosage form. The Company has completed Investigational New Drug, or IND, enabling preclinical studies of APR-548 and is targeting the submission of an IND in the first half of 2020.

ShowHide Related Items >><<
APRE Aprea Therapeutics
$34.00 /

+0.32 (+0.95%)

APRE Aprea Therapeutics
$34.00 /

+0.32 (+0.95%)

04/21/20
Fly Intel: Top five analyst initiations
04/20/20
Baird starts Aprea Therapeutics with Outperform on APR-246 potential
04/20/20 Baird
Aprea Therapeutics initiated with an Outperform at Baird
10/28/19 RBC Capital
Aprea Therapeutics initiated with an Outperform at RBC Capital
APRE Aprea Therapeutics
$34.00 /

+0.32 (+0.95%)

Hot Stocks
Aprea targets first patient enrollment in Phase 1/2 solid tumor trial in 2H20 » 07:36
05/15/20
05/15
07:36
05/15/20
07:36
APRE

Aprea Therapeutics

$34.00 /

+0.32 (+0.95%)

Based on in vivo data…

Based on in vivo data evidencing synergistic activity between APR-246 and immuno-therapy agents including anti-PD-1 antibody, the Company has designed and plans to conduct Phase 1/2 clinical trials in relapsed/refractory gastric, bladder and non-small cell lung cancers assessing APR-246 with anti-PD-1 therapy. The Company is targeting the first patient to be enrolled in the second half of 2020.

ShowHide Related Items >><<
APRE Aprea Therapeutics
$34.00 /

+0.32 (+0.95%)

APRE Aprea Therapeutics
$34.00 /

+0.32 (+0.95%)

04/21/20
Fly Intel: Top five analyst initiations
04/20/20
Baird starts Aprea Therapeutics with Outperform on APR-246 potential
04/20/20 Baird
Aprea Therapeutics initiated with an Outperform at Baird
10/28/19 RBC Capital
Aprea Therapeutics initiated with an Outperform at RBC Capital
APRE Aprea Therapeutics
$34.00 /

+0.32 (+0.95%)

Hot Stocks
Aprea Therapeutics targets first patient enrollment in Phase 1 NHL trial in 2H20 » 07:35
05/15/20
05/15
07:35
05/15/20
07:35
APRE

Aprea Therapeutics

$34.00 /

+0.32 (+0.95%)

As further assessment of…

As further assessment of APR-246 in hematological malignancies, the Company has designed and plans to conduct a Phase 1 clinical trial in relapsed/refractory TP53 mutant chronic lymphoid leukemia and mantle cell lymphoma assessing APR-246 with venetoclax and rituximab, and APR-246 with ibrutinib. The Company is targeting the first patient to be enrolled in the second half of 2020.

ShowHide Related Items >><<
APRE Aprea Therapeutics
$34.00 /

+0.32 (+0.95%)

APRE Aprea Therapeutics
$34.00 /

+0.32 (+0.95%)

04/21/20
Fly Intel: Top five analyst initiations
04/20/20
Baird starts Aprea Therapeutics with Outperform on APR-246 potential
04/20/20 Baird
Aprea Therapeutics initiated with an Outperform at Baird
10/28/19 RBC Capital
Aprea Therapeutics initiated with an Outperform at RBC Capital
APRE Aprea Therapeutics
$34.00 /

+0.32 (+0.95%)

Hot Stocks
Aprea Therapeutics expects to complete enrollment in Phase 2 MDS/AML trial in 3Q » 07:34
05/15/20
05/15
07:34
05/15/20
07:34
APRE

Aprea Therapeutics

$34.00 /

+0.32 (+0.95%)

The Company is currently…

The Company is currently enrolling its single-arm, open-label Phase 2 trial evaluating APR-246 with azacitidine as post-transplant maintenance therapy in TP53 mutant MDS and acute myeloid leukemia patients who have received an allogeneic stem cell transplant. Though the Company had initially observed a decrease in both patient screening and patient enrollment as a result of the COVID-19 pandemic, the Company has recently observed increased patient screening activity and has currently enrolled 16 out of 31 patients in this trial with a number of additional patients scheduled for screening. The Company believes that it will complete enrollment in this trial in the third quarter of 2020.

ShowHide Related Items >><<
APRE Aprea Therapeutics
$34.00 /

+0.32 (+0.95%)

APRE Aprea Therapeutics
$34.00 /

+0.32 (+0.95%)

04/21/20
Fly Intel: Top five analyst initiations
04/20/20
Baird starts Aprea Therapeutics with Outperform on APR-246 potential
04/20/20 Baird
Aprea Therapeutics initiated with an Outperform at Baird
10/28/19 RBC Capital
Aprea Therapeutics initiated with an Outperform at RBC Capital
APRE Aprea Therapeutics
$34.00 /

+0.32 (+0.95%)

Hot Stocks
Aprea Therapeutics expects to close enrollment in Phase 3 MDS trial in 2Q20 » 07:33
05/15/20
05/15
07:33
05/15/20
07:33
APRE

Aprea Therapeutics

$34.00 /

+0.32 (+0.95%)

The Company is currently…

The Company is currently enrolling a pivotal Phase 3 randomized, controlled trial evaluating APR-246 with azacitidine as frontline therapy in HMA-naive TP53 mutant myelodysplastic syndromes patients with a primary endpoint of CR rate. Though the Company had initially observed a decrease in both patient screening and patient enrollment as a result of the coronavirus pandemic, the Company has recently observed increased patient screening activity and has currently enrolled 140 patients in the trial with a number of additional patients now scheduled for screening. The Company currently plans to close enrollment of this trial in the second quarter of 2020 and remains confident it will have top-line data available by year-end 2020.

ShowHide Related Items >><<
APRE Aprea Therapeutics
$34.00 /

+0.32 (+0.95%)

APRE Aprea Therapeutics
$34.00 /

+0.32 (+0.95%)

04/21/20
Fly Intel: Top five analyst initiations
04/20/20
Baird starts Aprea Therapeutics with Outperform on APR-246 potential
04/20/20 Baird
Aprea Therapeutics initiated with an Outperform at Baird
10/28/19 RBC Capital
Aprea Therapeutics initiated with an Outperform at RBC Capital
APRE Aprea Therapeutics
$34.00 /

+0.32 (+0.95%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.